C ognitive-behavioural therapy (CBT) for depression is an empirically validated, time-limited psychotherapy that leverages awareness of mood-linked changes in cognition and phenomenology to teach patients suffering from depression effective means to regulate affect and reduce symptoms. Its current standing as a front-line treatment for mood disorders can be traced to changes in the scientific study of psychotherapy outcomes that began over 30 years ago. CBT was one of the first psychotherapies for depression to be evaluated against active contrast conditions such as antidepressant pharmacotherapy. When the results of these trials indicated a rough parity in clinical outcomes, 1-3 the efficacy of psychological treatment for depression could no longer be dismissed. In the same vein, the publication of Cognitive Therapy for Depression 4 represented one of the first attempts to detail step-by-step therapy procedures for conceptualizing depression as the product of biased mental representation as well as behavioural and cognitive strategies designed to address this. The expansion of CBT treatments for anxiety, eating, and substance use disorders was premised on the same combination of compelling clinical evidence and the explication of technique.
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Well over a quarter of a century later, it might be tempting to conclude that the treatment of mood disorders within a cognitive-behavioural frame is a project largely completedyet challenges do remain. This issue's In Review section provides a view of the field that is both prospective and retrospective. It strives to look beyond the modal applications of CBT in mood disorders to highlight areas of potential future investigation and application. The section's pair of articles speak to the ever-expanding role of CBT in mood disorders. Kuyken et al 5 report the most up-to-date conceptualizations of unipolar depression in the context of the cognitive model. In particular, they emphasize the diathesis-stress approach and multilevel schematic models to illuminate the intersection between biological vulnerability and psychopathology. Their writing also touches on some exciting new lines of evidence exploring the "active ingredient in CBT" and predictors of outcome.
We are now beginning to collect evidence from neuroimaging studies to illustrate brain changes associated with effective CBT. These kinds of studies are at the vanguard of psychotherapy research. In particular, Goldapple et al 6 have used functional imaging studies to demonstrate a different pattern of response in the brain when CBT is compared with paroxetine in the context of unipolar depression. Brain images of depression patients treated with paroxetine showed increased brain activity in the lateral cortices and suppression of limbic circuits in both the hippocampus and the subgenual cingulate, Area 25. In the same study, treatment response was associated with significant increases in hippocampal and dorsal cingulate activity and decreased activity in the dorsal, ventral, and medial frontal cortex. These opposite changes with CBT (relative to medication) in predominantly cortical brain regions, such as the medial frontal and dorsal cingulate, have been postulated to reflect regions primarily associated with attention, self-references, and reappraisal-areas specifically targeted by this form of psychotherapy.
Characterization of adaptive and maladaptive functional interactions among these pathways is a critical step toward future development of evidenced-based algorithms that will optimize the diagnosis and treatment of individual patients suffering from depression. Further work by Siegle et al 7 with fMRI has shown that patients whose sustained reactivity to emotional stimuli was low in the subgenual cingulated cortex and high in the amygdala displayed the strongest improvement with CBT. These novel lines of research are beginning to narrow the gap between brain and mind, informing not only an integrated depression network model but also clinical choices for treatment suitability and prognosis. In the future, targeted interventions based on unique biology and psychological vulnerability may be developed. This seems to be the natural progression and evolution of the individualized cognitive conceptualization that is already a cornerstone of cognitive therapy. 8 The Of particular note are their reports of clinical trials suggesting that CBT reduces the likelihood of relapse and may be antidepressant-sparing, thus reducing the risk of cycle acceleration. This recent, innovative work has challenged the idea that bipolar disorder is a biological illness to be treated solely with medication. Beck's original characterization of bipolar disorder viewed mania as a mirror of depression, characterized by a positive cognitive triad involving the self, the world, and the future together with cognitive distortions. 10 Although this understanding has evolved, there is an ongoing need for a more comprehensive cognitive model of bipolar disorder. At present, many issues with respect to the limits of the psychological component of bipolar affective disorder are still unresolved. The effective ceiling on the use of cognitive interventions within disorders that have a more organic base remains a mystery. Will CBT be used to simply enhance medication compliance, maintain social and diurnal rhythms, and facilitate antidepressantsparing, or most ambitiously, will CBT be used to resolve core psychological issues in bipolar disorder? The complex, integrated biopsychosocial models that are emerging for unipolar depression are still in their infancy with respect to their application to bipolar illness.
As mental health professionals, we often, and justifiably, concentrate our resources on populations that have already met the clinical threshold of disease. Most clinical practice is devoted to patients with an identifiable Axis I or Axis II disorder. Nevertheless, it is clear that many people suffer from a subclinical affective syndrome that might benefit from our most effective psychological interventions. Indeed, the early evidence from studies of mindfulness training 11 for relapse prevention or wellness-informed CBT treatment 12 of partial responders is promising.
Thinking even more broadly, the WHO has defined primary prevention as "the stage of prevention that covers all activities designed to reduce the instances of an illness in a population and thus to reduce, as far as possible, the risk of new cases." 13, p17 Were it possible to use CBT and psychoeducation as the nidus for interventions that reduce the stress burden on an individual, we might be able to prevent the stress term in the stress-diathesis equation from reaching the plateau of pathology.
Critics may claim that a psychoeducational intervention based on CBT principles cannot be broadly implemented. To that we can only agree. Material and human resources render accessibility to CBT-based interventions a limiting factor in their effectiveness. However, there is certainly precedent for nonpharmacologic, population-based interventions, ranging from routine blood pressure monitoring to infant screening. Broadly speaking, these interventions have been funded because they proved cost-effective in reducing the burden of illness in our country, and the next generation of CBT may well have the power to accomplish a similar feat.
The articles in this issue represent the leading edge of a psychological technology. They also identify novel and persistent questions about the nature of mood disorders and the complex interactions between neurobiology and psychology. They highlight some of the innovative research that seeks answers to these fundamental questions.
